cached image

Lars Lannfelt, MD PhD - Publications

Affiliations: 
Molecular Geriatrics Uppsala University, Uppsala, Uppsala län, Sweden 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=108
Website:
http://www.pubcare.uu.se/molekyl/index_en.shtml

264 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Johannesson M, Söderberg L, Zachrisson O, Fritz N, Kylefjord H, Gkanatsiou E, Button E, Svensson AS, Rachalski A, Nygren P, Osswald G, Lannfelt L, Möller C. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neurosciences. 130: 103949. PMID 38906341 DOI: 10.1016/j.mcn.2024.103949  0.421
2024 Rizoska B, Zachrisson O, Appelkvist P, Boström E, Björklund M, Rachalski A, Gkanatsiou E, Kylefjord H, Söderberg L, Nygren P, Eriksson F, Ishikawa Y, Fukushima T, Koyama A, Osswald G, ... Lannfelt L, et al. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice. Molecular and Cellular Neurosciences. 130: 103950. PMID 38901655 DOI: 10.1016/j.mcn.2024.103950  0.389
2024 Söderberg L, Johannesson M, Gkanatsiou E, Nygren P, Fritz N, Zachrisson O, Rachalski A, Svensson AS, Button E, Dentoni G, Osswald G, Lannfelt L, Möller C. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Scientific Reports. 14: 10868. PMID 38740836 DOI: 10.1038/s41598-024-61691-2  0.312
2024 Pagnon de la Vega M, Syvänen S, Giedraitis V, Hooley M, Konstantinidis E, Meier SR, Rokka J, Eriksson J, Aguilar X, Spires-Jones TL, Lannfelt L, Nilsson LNG, Erlandsson A, Hultqvist G, Ingelsson M, et al. Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion. Acta Neuropathologica Communications. 12: 22. PMID 38317196 DOI: 10.1186/s40478-024-01734-x  0.427
2023 Lannfelt L. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease. Upsala Journal of Medical Sciences. 128. PMID 38084203 DOI: 10.48101/ujms.v128.10316  0.461
2023 Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, et al. The amyloid-β pathway in Alzheimer's disease: a plain language summary. Neurodegenerative Disease Management. PMID 36994753 DOI: 10.2217/nmt-2022-0037  0.362
2022 Condello C, Maxwell AM, Castillo E, Aoyagi A, Graff C, Ingelsson M, Lannfelt L, Bird TD, Keene CD, Seeley WW, Perl DP, Head E, Prusiner SB. Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 119: e2212954119. PMID 36343257 DOI: 10.1073/pnas.2212954119  0.38
2022 Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 36253511 DOI: 10.1007/s13311-022-01308-6  0.333
2022 Pagnon de la Vega M, Näslund C, Brundin R, Lannfelt L, Löwenmark M, Kilander L, Ingelsson M, Giedraitis V. Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia. Bmc Genomics. 23: 99. PMID 35120450 DOI: 10.1186/s12864-022-08343-9  0.446
2021 Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, Metzendorf NG, Gustavsson T, Sehlin D, Söderberg L, Hultqvist G. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Translational Neurodegeneration. 10: 38. PMID 34579778 DOI: 10.1186/s40035-021-00258-x  0.352
2021 Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry. PMID 34456336 DOI: 10.1038/s41380-021-01249-0  0.405
2021 Pagnon de la Vega M, Giedraitis V, Michno W, Kilander L, Güner G, Zielinski M, Löwenmark M, Brundin R, Danfors T, Söderberg L, Alafuzoff I, Nilsson LNG, Erlandsson A, Willbold D, Müller SA, ... ... Lannfelt L, et al. The deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. Science Translational Medicine. 13. PMID 34380771 DOI: 10.1126/scitranslmed.abc6184  0.514
2021 Johannesson M, Sahlin C, Söderberg L, Basun H, Fälting J, Möller C, Zachrisson O, Sunnemark D, Svensson A, Odergren T, Lannfelt L. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease. Molecular and Cellular Neurosciences. 114: 103641. PMID 34091073 DOI: 10.1016/j.mcn.2021.103641  0.404
2021 Zhang X, O'Callaghan P, Li H, Tan Y, Zhang G, Barash U, Wang X, Lannfelt L, Vlodavsky I, Lindahl U, Li JP. Heparanase overexpression impedes perivascular clearance of amyloid-β from murine brain: relevance to Alzheimer's disease. Acta Neuropathologica Communications. 9: 84. PMID 33971986 DOI: 10.1186/s40478-021-01182-x  0.365
2021 Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Research & Therapy. 13: 80. PMID 33865446 DOI: 10.1186/s13195-021-00813-8  0.373
2021 Gkanatsiou E, Sahlin C, Portelius E, Johannesson M, Söderberg L, Fälting J, Basun H, Möller C, Odergren T, Zetterberg H, Blennow K, Lannfelt L, Brinkmalm G. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. Neuroscience Letters. 754: 135894. PMID 33848613 DOI: 10.1016/j.neulet.2021.135894  0.43
2020 Bogdanovic N, Hansson O, Zetterberg H, Basun H, Ingelsson M, Lannfelt L, Blennow K. [Alzheimer's disease - the most common cause of dementia]. Lakartidningen. 117. PMID 32154904  0.399
2019 Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, ... ... Lannfelt L, et al. Author Correction: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. PMID 31417202 DOI: 10.1038/s41588-019-0495-7  0.309
2019 Aoyagi A, Condello C, Stöhr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Keene CD, Seeley WW, et al. Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. Science Translational Medicine. 11. PMID 31043574 DOI: 10.1126/Scitranslmed.Aat8462  0.425
2019 Khoonsari PE, Shevchenko G, Herman S, Remnestål J, Giedraitis V, Brundin R, Gunnarsson MD, Kilander L, Zetterberg H, Nilsson P, Lannfelt L, Ingelsson M, Kultima K. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease : Jad. PMID 30614806 DOI: 10.3233/Jad-180855  0.472
2018 Sardar Sinha M, Ansell-Schultz A, Civitelli L, Hildesjö C, Larsson M, Lannfelt L, Ingelsson M, Hallbeck M. Alzheimer's disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathologica. 136: 41-56. PMID 29934873 DOI: 10.1007/s00401-018-1868-1  0.383
2018 György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, et al. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy. Nucleic Acids. 11: 429-440. PMID 29858078 DOI: 10.1016/J.Omtn.2018.03.007  0.491
2018 Meier SR, Syvänen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, Neumann U, Sehlin D. Antibody-based in vivo PET imaging detects amyloid-β reduction in Alzheimer transgenic mice after BACE-1 inhibition. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29853653 DOI: 10.2967/jnumed.118.213140  0.322
2018 Syvänen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, Söderberg L, Ingelsson M, Lannfelt L, Sehlin D. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimer's Research & Therapy. 10: 49. PMID 29793530 DOI: 10.1186/s13195-018-0377-8  0.382
2018 Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, Lannfelt L, Erlandsson A. The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. Journal of Neuroinflammation. 15: 98. PMID 29592816 DOI: 10.1186/s12974-018-1134-4  0.381
2018 Condello C, Lemmin T, Stöhr J, Nick M, Wu Y, Maxwell AM, Watts JC, Caro CD, Oehler A, Keene CD, Bird TD, van Duinen SG, Lannfelt L, Ingelsson M, Graff C, et al. Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 29311311 DOI: 10.1073/Pnas.1714966115  0.443
2017 Velickaite V, Giedraitis V, Ström K, Alafuzoff I, Zetterberg H, Lannfelt L, Kilander L, Larsson E, Ingelsson M. Cognitive function in very old men does not correlate to biomarkers of Alzheimer’s disease Bmc Geriatrics. 17: 208-208. PMID 28886705 DOI: 10.1186/S12877-017-0601-6  0.422
2017 Abu Hamdeh S, Waara ER, Möller C, Söderberg L, Basun H, Alafuzoff I, Hillered L, Lannfelt L, Ingelsson M, Marklund N. Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury. Brain Pathology (Zurich, Switzerland). PMID 28557010 DOI: 10.1111/Bpa.12532  0.377
2017 Westman G, Blomberg J, Yun Z, Lannfelt L, Ingelsson M, Eriksson BM. Decreased HHV-6 IgG in Alzheimer's Disease. Frontiers in Neurology. 8: 40. PMID 28265256 DOI: 10.3389/fneur.2017.00040  0.339
2016 Fang XT, Eriksson J, Antoni G, Yngve U, Cato L, Lannfelt L, Sehlin D, Syvänen S. Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting. Neuropharmacology. PMID 27743932 DOI: 10.1016/j.neuropharm.2016.10.009  0.311
2016 Musunuri S, Khoonsari PE, Mikus M, Wetterhall M, Häggmark A, Lannfelt L, Erlandsson A, Bergquist J, Ingelsson M, Shevchenko G, Nilsson P, Kultima K. Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain. Journal of Alzheimer's Disease : Jad. PMID 27636840 DOI: 10.3233/JAD-160271  0.456
2016 Degerman Gunnarsson M, Ingelsson M, Blennow K, Basun H, Lannfelt L, Kilander L. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. Alzheimer's Research & Therapy. 8: 22. PMID 27263933 DOI: 10.1186/S13195-016-0191-0  0.474
2016 Dumanski JP, Lambert JC, Rasi C, Giedraitis V, Davies H, Grenier-Boley B, Lindgren CM, Campion D, Dufouil C, Pasquier F, Amouyel P, Lannfelt L, Ingelsson M, Kilander L, et al. Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American Journal of Human Genetics. PMID 27231129 DOI: 10.1016/J.Ajhg.2016.05.014  0.318
2016 Söllvander S, Nikitidou E, Brolin R, Söderberg L, Sehlin D, Lannfelt L, Erlandsson A. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Molecular Neurodegeneration. 11: 38. PMID 27176225 DOI: 10.1186/s13024-016-0098-z  0.332
2016 Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimer's Research & Therapy. 8: 14. PMID 27048170 DOI: 10.1186/s13195-016-0181-2  0.346
2016 Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, Wiltfang J, Kovacs GG, Ingelsson M, Lannfelt L, Paetau A, Bergquist J, Wirths O. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models. Acta Neuropathologica Communications. 4: 24. PMID 26955942 DOI: 10.1186/S40478-016-0294-7  0.476
2016 Khoonsari PE, Häggmark A, Lönnberg M, Mikus M, Kilander L, Lannfelt L, Bergquist J, Ingelsson M, Nilsson P, Kultima K, Shevchenko G. Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease. Plos One. 11: e0150672. PMID 26950848 DOI: 10.1371/journal.pone.0150672  0.373
2016 Gyorgy B, Ingelsson M, Loov C, Takeda S, Lannfelt L, Hyman BT, Breakefield XO. 567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease Molecular Therapy. 24: S226-S227. DOI: 10.1016/S1525-0016(16)33375-5  0.392
2015 Söllvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S, Lannfelt L, Sehlin D, Piazza F. Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 48: 63-72. PMID 26401929 DOI: 10.3233/JAD-150236  0.364
2015 Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. Journal of Alzheimer's Disease : Jad. 43: 575-88. PMID 25096615 DOI: 10.3233/JAD-140741  0.349
2015 Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. Corrigendum to "The amyloid-beta degradation pattern in plasma-A possible tool for clinical trials in Alzheimer's disease" [Neurosci. Lett. 573 (2014) 7-12] DOI: 10.1016/j.neulet.2014.04.041 Neuroscience Letters. 599: 67-68. DOI: 10.1016/j.neulet.2015.05.042  0.309
2014 Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's Research & Therapy. 6: 16. PMID 25031633 DOI: 10.1186/alzrt246  0.35
2014 Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America. 111: 10323-8. PMID 24982139 DOI: 10.1073/Pnas.1408900111  0.374
2014 Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters. 573: 7-12. PMID 24796810 DOI: 10.1016/j.neulet.2014.04.041  0.399
2014 Guzmán EA, Bouter Y, Richard BC, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Wirths O, Bayer TA. Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. Molecular Neurodegeneration. 9: 13. PMID 24694184 DOI: 10.1186/1750-1326-9-13  0.463
2014 Musunuri S, Wetterhall M, Ingelsson M, Lannfelt L, Artemenko K, Bergquist J, Kultima K, Shevchenko G. Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry. Journal of Proteome Research. 13: 2056-68. PMID 24606058 DOI: 10.1021/pr401202d  0.379
2014 Lannfelt L, Relkin NR, Siemers ER. Amyloid-ß-directed immunotherapy for Alzheimer's disease. Journal of Internal Medicine. 275: 284-95. PMID 24605809 DOI: 10.1111/joim.12168  0.306
2014 O'Callaghan P, Noborn F, Sehlin D, Li JP, Lannfelt L, Lindahl U, Zhang X. Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 21: 76-87. PMID 24491019 DOI: 10.3109/13506129.2013.879643  0.429
2014 Reinert J, Martens H, Huettenrauch M, Kolbow T, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Bayer TA, Wirths O. Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. Journal of Alzheimer's Disease : Jad. 39: 871-81. PMID 24305500 DOI: 10.3233/Jad-131373  0.322
2014 Degerman Gunnarsson M, Lannfelt L, Ingelsson M, Basun H, Kilander L. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 37: 196-206. PMID 24157938 DOI: 10.1159/000355556  0.374
2014 Swanson CJ, Logovinsky V, Xu L, Wang J, Lai R, Rabe MP, Gordon R, Kaplow JM, Basun H, Lannfelt L, Satlin A. P3-404: CONSIDERATION FOR “EARLY ALZHEIMER'S DISEASE (AD)” TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401-G000-201 TRIAL Alzheimer's & Dementia. 10: P778-P778. DOI: 10.1016/j.jalz.2014.05.1499  0.347
2013 Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, Wirths O, Bayer TA, Nilsson LN, Basun H, ... Lannfelt L, et al. The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ. Acta Neuropathologica Communications. 1: 60. PMID 24252272 DOI: 10.1186/2051-5960-1-60  0.493
2013 Antonios G, Saiepour N, Bouter Y, Richard BC, Paetau A, Verkkoniemi-Ahola A, Lannfelt L, Ingelsson M, Kovacs GG, Pillot T, Wirths O, Bayer TA. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathologica Communications. 1: 56. PMID 24252153 DOI: 10.1186/2051-5960-1-56  0.44
2013 Rubio-Moscardo F, Setó-Salvia N, Pera M, Bosch-Morató M, Plata C, Belbin O, Gené G, Dols-Icardo O, Ingelsson M, Helisalmi S, Soininen H, Hiltunen M, Giedraitis V, Lannfelt L, Frank A, et al. Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis. Plos One. 8: e74203. PMID 24069280 DOI: 10.1371/Journal.Pone.0074203  0.323
2013 Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Tucker SM, Kasaryan A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L, Ingelsson M, Bergström J. Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 20: 233-44. PMID 24053224 DOI: 10.3109/13506129.2013.835726  0.302
2013 Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, Antoni G, Lannfelt L, Hall H, Nilsson LN. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. Journal of Alzheimer's Disease : Jad. 37: 29-40. PMID 23780660 DOI: 10.3233/JAD-130029  0.342
2013 Roed L, Grave G, Lindahl T, Rian E, Horndalsveen PO, Lannfelt L, Nilsson C, Swenson F, Lönneborg A, Sharma P, Sjögren M. Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study. Journal of Alzheimer's Disease : Jad. 35: 611-21. PMID 23478308 DOI: 10.3233/JAD-122404  0.325
2013 Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. Journal of Alzheimer's Disease : Jad. 34: 673-9. PMID 23254629 DOI: 10.3233/JAD-121384  0.388
2013 Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. Journal of Alzheimer's Disease : Jad. 33: 45-53. PMID 22890100 DOI: 10.3233/JAD-2012-120787  0.367
2012 Zhang X, Wang B, O'Callaghan P, Hjertström E, Jia J, Gong F, Zcharia E, Nilsson LN, Lannfelt L, Vlodavsky I, Lindahl U, Li JP. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathologica. 124: 465-78. PMID 22692572 DOI: 10.1007/s00401-012-0997-1  0.305
2012 Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. Plos One. 7: e32014. PMID 22355408 DOI: 10.1371/journal.pone.0032014  0.37
2012 Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, Bogdanovic N, Olofsson T, Tjernberg LO, Ingelsson M, Lannfelt L, Kalimo H, Nilsson LN. The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ. Neurobiology of Aging. 33: 1010.e1-13. PMID 22118948 DOI: 10.1016/J.Neurobiolaging.2011.10.022  0.451
2012 Lannfelt L. S.25.04 Immunotherapy in Alzheimer's disease – targeting toxic Aβ protofibrils European Neuropsychopharmacology. 22: S143. DOI: 10.1016/S0924-977X(12)70193-1  0.358
2011 Santillo AF, Gambini JP, Lannfelt L, LÃ¥ngström B, Ulla-Marja L, Kilander L, Engler H. In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study. European Journal of Nuclear Medicine and Molecular Imaging. 38: 2202-8. PMID 21853308 DOI: 10.1007/s00259-011-1895-9  0.35
2011 Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies. Neuro-Degenerative Diseases. 8: 117-23. PMID 20714111 DOI: 10.1159/000316530  0.393
2011 Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease. Neurobiology of Aging. 32: 1379-87. PMID 19781815 DOI: 10.1016/j.neurobiolaging.2009.08.011  0.354
2010 Blom ES, Wang Y, Skoglund L, Hansson AC, Ubaldi M, Lourdusamy A, Sommer WH, Mielke M, Hyman BT, Heilig M, Lannfelt L, Nilsson LN, Ingelsson M. Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain. International Journal of Alzheimer's Disease. 2011: 936580. PMID 21234373 DOI: 10.4061/2011/936580  0.308
2010 Lannfelt L, Pettersson FE, Nilsson LN. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. Nutrition Reviews. 68: S128-34. PMID 21091946 DOI: 10.1111/j.1753-4887.2010.00347.x  0.402
2010 Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. The Journal of Biological Chemistry. 285: 41517-24. PMID 20971852 DOI: 10.1074/Jbc.M110.178707  0.412
2010 Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. Journal of Alzheimer's Disease : Jad. 22: 1223-30. PMID 20930303 DOI: 10.3233/JAD-2010-101023  0.319
2010 Kamali-Moghaddam M, Pettersson FE, Wu D, Englund H, Darmanis S, Lord A, Tavoosidana G, Sehlin D, Gustafsdottir S, Nilsson LN, Lannfelt L, Landegren U. Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. Bmc Neuroscience. 11: 124. PMID 20923550 DOI: 10.1186/1471-2202-11-124  0.303
2010 Lambert JC, Sleegers K, González-Pérez A, Ingelsson M, Beecham GW, Hiltunen M, Combarros O, Bullido MJ, Brouwers N, Bettens K, Berr C, Pasquier F, Richard F, Dekosky ST, Hannequin D, ... ... Lannfelt L, et al. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. Journal of Alzheimer's Disease : Jad. 22: 247-55. PMID 20847397 DOI: 10.3233/Jad-2010-100933  0.343
2010 Sandberg A, Luheshi LM, Söllvander S, Pereira de Barros T, Macao B, Knowles TP, BiverstÃ¥l H, Lendel C, Ekholm-Petterson F, Dubnovitsky A, Lannfelt L, Dobson CM, Härd T. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proceedings of the National Academy of Sciences of the United States of America. 107: 15595-600. PMID 20713699 DOI: 10.1073/Pnas.1001740107  0.406
2010 Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Journal of Alzheimer's Disease : Jad. 21: 471-8. PMID 20555147 DOI: 10.3233/JAD-2010-091594  0.388
2010 Wiberg H, Ek P, Pettersson FE, Lannfelt L, Emmer A, Roeraade J. Separation and characterization of aggregated species of amyloid-beta peptides. Analytical and Bioanalytical Chemistry. 397: 2357-66. PMID 20502882 DOI: 10.1007/s00216-010-3839-9  0.308
2010 Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dementia and Geriatric Cognitive Disorders. 29: 204-12. PMID 20332638 DOI: 10.1159/000281832  0.359
2010 Philipson O, Lord A, Gumucio A, O'Callaghan P, Lannfelt L, Nilsson LN. Animal models of amyloid-beta-related pathologies in Alzheimer's disease. The Febs Journal. 277: 1389-409. PMID 20136653 DOI: 10.1111/j.1742-4658.2010.07564.x  0.395
2010 Sandwall E, O'Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP. Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology. 20: 533-41. PMID 20053627 DOI: 10.1093/glycob/cwp205  0.394
2010 Giedraitis V, Glaser A, Sarajärvi T, Brundin R, Gunnarsson MD, Schjeide BM, Tanzi RE, Helisalmi S, Pirttilä T, Kilander L, Lannfelt L, Soininen H, Bertram L, Ingelsson M, Hiltunen M. CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neuroscience Letters. 469: 265-7. PMID 20005921 DOI: 10.1016/J.Neulet.2009.12.011  0.366
2010 Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 85-96. PMID 19823761 DOI: 10.1007/S00702-009-0314-X  0.465
2010 Wiig EH, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurologica Scandinavica. 121: 186-93. PMID 19785641 DOI: 10.1111/j.1600-0404.2009.01160.x  0.33
2009 Skoglund L, Ingvast S, Matsui T, Freeman SH, Frosch MP, Brundin R, Giedraitis V, Growdon JH, Hyman BT, Lannfelt L, Ingelsson M, Glaser A. No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. Dementia and Geriatric Cognitive Disorders. 28: 471-5. PMID 19940479 DOI: 10.1159/000260046  0.307
2009 Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Söderberg L, Möller C, Gellerfors P, Lannfelt L, Pettersson FE, Nilsson LN. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease. 36: 425-34. PMID 19703562 DOI: 10.1016/j.nbd.2009.08.007  0.44
2009 Philipson O, Lannfelt L, Nilsson LN. Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice. Febs Letters. 583: 3021-6. PMID 19683527 DOI: 10.1016/j.febslet.2009.08.009  0.387
2009 Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neuro-Degenerative Diseases. 6: 139-47. PMID 19521063 DOI: 10.1159/000225376  0.451
2009 Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dementia and Geriatric Cognitive Disorders. 27: 458-64. PMID 19420940 DOI: 10.1159/000216841  0.411
2009 Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 913-20. PMID 19415450 DOI: 10.1007/s00702-009-0224-y  0.395
2009 Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry. 46: 235-40. PMID 19342441 DOI: 10.1258/Acb.2009.008232  0.341
2009 Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The Febs Journal. 276: 995-1006. PMID 19215301 DOI: 10.1111/J.1742-4658.2008.06836.X  0.368
2009 Giedraitis V, Kilander L, Degerman-Gunnarsson M, Sundelöf J, Axelsson T, Syvänen AC, Lannfelt L, Glaser A. Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dementia and Geriatric Cognitive Disorders. 27: 59-68. PMID 19141999 DOI: 10.1159/000191203  0.315
2009 Skoglund L, Brundin R, Olofsson T, Kalimo H, Ingvast S, Blom ES, Giedraitis V, Ingelsson M, Lannfelt L, Basun H, Glaser A. Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. Neurogenetics. 10: 27-34. PMID 18855025 DOI: 10.1007/S10048-008-0155-Z  0.303
2009 Philipson O, Hammarström P, Nilsson KP, Portelius E, Olofsson T, Ingelsson M, Hyman BT, Blennow K, Lannfelt L, Kalimo H, Nilsson LN. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiology of Aging. 30: 1393-405. PMID 18192084 DOI: 10.1016/J.Neurobiolaging.2007.11.022  0.436
2008 Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry MC, Giedraitis V, Rönnemaa E, Degerman-Gunnarsson M, Hyman BT, Basun H, Kilander L, Lannfelt L. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology. 71: 1072-9. PMID 18824671 DOI: 10.1212/01.wnl.0000326894.40353.93  0.316
2008 O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, Kalimo H, Lindahl U, Lannfelt L, Zhang X. Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathology (Zurich, Switzerland). 18: 548-61. PMID 18422760 DOI: 10.1111/J.1750-3639.2008.00152.X  0.436
2008 Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Näslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Archives of Neurology. 65: 499-505. PMID 18413473 DOI: 10.1001/Archneur.65.4.499  0.535
2008 Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Archives of Neurology. 65: 256-63. PMID 18268197 DOI: 10.1001/Archneurol.2007.57  0.422
2008 Skoglund L, Viitanen M, Kalimo H, Lannfelt L, Jönhagen ME, Ingelsson M, Glaser A, Herva R. The tau S305S mutation causes frontotemporal dementia with parkinsonism. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 15: 156-61. PMID 18093153 DOI: 10.1111/J.1468-1331.2007.02017.X  0.365
2008 Blom ES, Viswanathan J, Kilander L, Helisalmi S, Soininen H, Lannfelt L, Ingelsson M, Glaser A, Hiltunen M. Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. European Journal of Human Genetics : Ejhg. 16: 171-5. PMID 18043715 DOI: 10.1038/sj.ejhg.5201966  0.388
2008 Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, Lannfelt L, LÃ¥ngström B, Kilander L. In vivo amyloid imaging with PET in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging. 35: 100-6. PMID 17846768 DOI: 10.1007/S00259-007-0523-1  0.377
2008 Philipson O, Lord A, Olofsson T, Ingelsson M, Lannfelt L, Kalimo H, Nilsson LNG. P1-097: The arctic Alzheimer mutation alters structure and composition of Aβ deposits Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.683  0.395
2008 Englund H, Sehlin D, Gunnarsson MD, Lord A, Brundin R, Ingelsson M, Kilander L, Nilsson LN, Pettersson FE, Lannfelt L. O3-02-04: Increased levels of CSF Aβ oligomers in Alzheimer's disease: Combination of techniques allows indirect estimates Alzheimer's & Dementia. 4: T161-T161. DOI: 10.1016/j.jalz.2008.05.417  0.311
2008 Lindau MP, Gunnarsson MD, Santillo AF, Basun H, Lannfelt L, Kilander L. P3-026: Insight in frontotemporal dementia and Alzheimer's disease Alzheimer's & Dementia. 4: T524-T524. DOI: 10.1016/j.jalz.2008.05.1589  0.332
2007 Giedraitis V, Sundelöf J, Irizarry MC, GÃ¥revik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters. 427: 127-31. PMID 17936506 DOI: 10.1016/J.Neulet.2007.09.023  0.43
2007 Englund H, Annerén G, Gustafsson J, Wester U, Wiltfang J, Lannfelt L, Blennow K, Höglund K. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dementia and Geriatric Cognitive Disorders. 24: 369-74. PMID 17914261 DOI: 10.1159/000109215  0.368
2007 Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, Johansson AS. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. The European Journal of Neuroscience. 26: 882-9. PMID 17714184 DOI: 10.1111/j.1460-9568.2007.05719.x  0.44
2007 Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 24: 247-52. PMID 17700020 DOI: 10.1159/000107099  0.384
2007 Nilsson KP, Aslund A, Berg I, Nyström S, Konradsson P, Herland A, Inganäs O, Stabo-Eeg F, Lindgren M, Westermark GT, Lannfelt L, Nilsson LN, Hammarström P. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. Acs Chemical Biology. 2: 553-60. PMID 17672509 DOI: 10.1021/Cb700116U  0.4
2007 Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. Journal of Neurochemistry. 103: 334-45. PMID 17623042 DOI: 10.1111/j.1471-4159.2007.04759.x  0.456
2007 Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuroscience Letters. 419: 18-22. PMID 17482358 DOI: 10.1016/j.neulet.2007.03.064  0.395
2007 Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. Journal of Neurochemistry. 101: 854-62. PMID 17448150 DOI: 10.1111/J.1471-4159.2006.04443.X  0.459
2007 Johansson AS, Bergquist J, Volbracht C, Päiviö A, Leist M, Lannfelt L, Westlind-Danielsson A. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport. 18: 559-63. PMID 17413657 DOI: 10.1097/WNR.0b013e3280b07c21  0.339
2007 Wollmer MA, Sleegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, Brunner F, Huynh KD, Kilander L, Brundin RM, Hedlund M, Giedraitis V, Glaser A, Engelborghs S, De Deyn PP, ... ... Lannfelt L, et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics. 8: 179-88. PMID 17387528 DOI: 10.1007/S10048-007-0087-Z  0.332
2006 Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L. Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. The Febs Journal. 273: 2618-30. PMID 16817891 DOI: 10.1111/j.1742-4658.2006.05263.x  0.347
2006 Ingelsson M, Ramasamy K, Cantuti-Castelvetri I, Skoglund L, Matsui T, Orne J, Kowa H, Raju S, Vanderburg CR, Augustinack JC, de Silva R, Lees AJ, Lannfelt L, Growdon JH, Frosch MP, et al. No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathologica. 112: 439-49. PMID 16802167 DOI: 10.1007/S00401-006-0095-3  0.344
2006 Murphy EJ, Huang HM, Cowburn RF, Lannfelt L, Gibson GE. Phospholipid mass is increased in fibroblasts bearing the Swedish amyloid precursor mutation. Brain Research Bulletin. 69: 79-85. PMID 16464688 DOI: 10.1016/j.brainresbull.2005.10.012  0.3
2006 Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiology of Aging. 27: 67-77. PMID 16298242 DOI: 10.1016/J.Neurobiolaging.2004.12.007  0.432
2006 Condello C, Aoyagi A, Stöhr J, Lee JC, Rivera BM, Woerman AL, Halliday GM, van Duinen S, Ingelsson M, Lannfelt L, Graff C, Bird TD, Dirk Keene C, Seeley WW, DeGrado WF, et al. P4-233: AGED ALZHEIMER'S DISEASE BRAINS EXHIBIT NUMEROUS Aβ BUT ONLY FEW TAU PRIONS Alzheimer's & Dementia. 14: P1531-P1532. DOI: 10.1016/J.Jalz.2018.07.054  0.369
2006 Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RY, Lannfelt L, Kramer LD, Luthman J. DT-01-07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI-Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE Alzheimer's & Dementia. 14: P1668-P1668. DOI: 10.1016/j.jalz.2018.07.009  0.33
2006 Callaghan PO, Yu H, Nilsson LNG, Ingelsson M, Hyman BT, Li J, Lindahl U, Lannfelt L, Zhang X. P1-387: Comparative analysis of heparan sulfate co-localization with Aβ40 and Aβ42 in different Aβ deposits of APP transgenic mice and Alzheimer’s disease patients Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.765  0.373
2006 Philipsson O, Portelius E, Olofsson T, Kalimo H, Blennow K, Lannfelt L, Nilsson LNG. P1-038: Immunohistochemical and biochemical analyses of Aβ deposits in Tg-APP-ArcSwe and Tg-APP-Swe transgenic mouse brain Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.413  0.321
2006 Lord A, Englund H, Sehlin D, Ekholm-Pettersson F, Lannfelt L, Nilsson L. P4-277: Targeting Aβ oligomers in Alzheimer's disease transgenic mice carrying the Arctic and Swedish mutations Alzheimer's & Dementia. 2: S598-S598. DOI: 10.1016/j.jalz.2006.05.2016  0.403
2006 Stenh C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LNG. AbstractPoster presentation: Wednesday posterP4-041: The Arctic Alzheimer mutation favors Aβ production by making APP less available to α-secretase at the cell surface Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1779  0.378
2006 Skoglund L, Kalimo H, Herva R, Ingelsson M, Lannfelt L, Glaser A, Viitanen M. P3-150: Frontotemporal dementia and parkinsonism: A new phenotype of the tau S305S mutation Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1418  0.335
2006 Engler HW, Louhija UM, Savitcheva I, Olofsson T, Kalimo H, Lannfelt L, Långström BR. AbstractPoster presentation: Monday posterP2-273: PET-imaging of amyloid depositions and astrocytosis in severe ad and histopathological correlations in one patient Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1112  0.3
2005 Selle H, Lamerz J, Buerger K, Dessauer A, Hager K, Hampel H, Karl J, Kellmann M, Lannfelt L, Louhija J, Riepe M, Rollinger W, Tumani H, Schrader M, Zucht HD. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Combinatorial Chemistry & High Throughput Screening. 8: 801-6. PMID 16464167 DOI: 10.2174/138620705774962391  0.326
2005 Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 6: 69-84. PMID 16156480 DOI: 10.1080/15622970510029786  0.336
2005 Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Annals of Neurology. 58: 147-50. PMID 15984012 DOI: 10.1002/Ana.20524  0.384
2005 Flood F, Murphy S, Cowburn RF, Lannfelt L, Walker B, Johnston JA. Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. The Biochemical Journal. 385: 545-50. PMID 15473868 DOI: 10.1042/BJ20041145  0.38
2004 Froelich-Fabre S, Skoglund L, Ostojic J, Kilander L, Lindau M, Glaser A, Basun H, Lannfelt L. Clinical and molecular aspects of frontotemporal dementia. Neuro-Degenerative Diseases. 1: 218-24. PMID 16908993 DOI: 10.1159/000080989  0.339
2004 Ostojic J, Elfgren C, Passant U, Nilsson K, Gustafson L, Lannfelt L, Froelich Fabre S. The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dementia and Geriatric Cognitive Disorders. 17: 298-301. PMID 15178940 DOI: 10.1159/000077158  0.414
2004 Johnson J, Ostojic J, Lannfelt L, Glaser A, Basun H, Rogaeva E, Kawarai T, Bruni A, St George Hyslop PH, Goate A, Pastor P, Chakraverty S, Norton J, Morris JC, Hardy J, et al. No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. Neuroscience Letters. 363: 99-101. PMID 15172093 DOI: 10.1016/J.Neulet.2004.03.070  0.308
2004 Päiviö A, Jarvet J, Gräslund A, Lannfelt L, Westlind-Danielsson A. Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. Journal of Molecular Biology. 339: 145-59. PMID 15123427 DOI: 10.1016/j.jmb.2004.03.028  0.413
2004 Lannfelt L, Lannfelt L. P2-268 Genetics, pathophysiology and Aβ protofibril formation in Alzheimer's disease Neurobiology of Aging. 25: S308. DOI: 10.1016/S0197-4580(04)81013-3  0.366
2004 Lord A, Zhang X, Lannfelt L, Nilsson LN. P2-082 New Alzheimer's transgenic mouse models harbouring the Swedish mutation and both the Swedish and arctic mutations Neurobiology of Aging. 25: S247. DOI: 10.1016/S0197-4580(04)80829-7  0.346
2004 Westlind-Danielsson A, Johansson A, Bergquist J, Volbracht C, Leist M, Lannfelt L. P1-198 Oxidation of Aβ1-42 and Aβ1-40E22G methionine 35 prevents the formation ofoligomers and protofibrils and inhibits in vitro neurotoxicity-implications for Alzheimer's disease Neurobiology of Aging. 25: S152. DOI: 10.1016/S0197-4580(04)80511-6  0.379
2004 Johansson A, Berglind-Dehlin F, Gellerfors P, Lannfelt L. P1-171 Physiochemical characterization of the Alzheimer's disease related peptides Aβ1-42WT and Aβ1-42 arctic Neurobiology of Aging. 25: S144. DOI: 10.1016/S0197-4580(04)80484-6  0.403
2004 Stenh C, Englund H, Almeida C, Greengard P, Nilsson L, Gouras G, Lannfelt L. O4-02-04 The arctic APP mutation affects Aβ production and its site of cellular aggregation in Alzheimer's disease Neurobiology of Aging. 25: S76. DOI: 10.1016/S0197-4580(04)80259-8  0.426
2003 Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Möller HJ, Hampel H, Davidsson P, Blennow K. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology. 183: 74-80. PMID 12957490 DOI: 10.1016/S0014-4886(03)00027-X  0.386
2003 Froelich Fabre S, Axelman P, Almkvist A, Basun H, Lannfelt L. Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 121: 112-8. PMID 12898585 DOI: 10.1002/ajmg.b.20067  0.308
2003 Bergman A, Religa D, Karlström H, Laudon H, Winblad B, Lannfelt L, Lundkvist J, Näslund J. APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations. Experimental Cell Research. 287: 1-9. PMID 12799176 DOI: 10.1016/S0014-4827(03)00117-4  0.416
2003 Almkvist O, Axelman K, Basun H, Jensen M, Viitanen M, Wahlund LO, Lannfelt L. Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. Acta Neurologica Scandinavica. Supplementum. 179: 77-82. PMID 12603253 DOI: 10.1034/J.1600-0404.107.S179.11.X  0.366
2003 Lannfelt L. S.03.05 Protofibrils in the pathogenesis of Alzheimer's disease European Neuropsychopharmacology. 13: S102. DOI: 10.1016/S0924-977X(03)91608-7  0.324
2002 Almkvist O, Axelman K, Basun H, Wahlund LO, Lannfelt L. Conversion from preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation. Journal of Neural Transmission. Supplementum. 117-25. PMID 12456057 DOI: 10.1007/978-3-7091-6139-5_12  0.327
2002 Stenh C, Nilsberth C, Hammarbäck J, Engvall B, Näslund J, Lannfelt L. The Arctic mutation interferes with processing of the amyloid precursor protein. Neuroreport. 13: 1857-60. PMID 12395079 DOI: 10.1097/00001756-200210280-00005  0.766
2002 Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dementia and Geriatric Cognitive Disorders. 14: 156-60. PMID 12218259 DOI: 10.1159/000063605  0.749
2002 Bogdanovic N, Corder E, Lannfelt L, Winblad B. APOE polymorphism and clinical duration determine regional neuropathology in Swedish APP(670, 671) mutation carriers: implications for late-onset Alzheimer's disease. Journal of Cellular and Molecular Medicine. 6: 199-214. PMID 12169205 DOI: 10.1111/J.1582-4934.2002.Tb00187.X  0.485
2002 Sennvik K, Nilsberth C, Stenh C, Lannfelt L, Benedikz E. The Arctic Alzheimer mutation enhances sensitivity to toxic stress in human neuroblastoma cells. Neuroscience Letters. 326: 51-5. PMID 12052536 DOI: 10.1016/S0304-3940(02)00305-1  0.751
2001 Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson JA, Lannfelt L. Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. European Journal of Human Genetics : Ejhg. 9: 802-4. PMID 11781694 DOI: 10.1038/Sj.Ejhg.5200714  0.478
2001 Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neuroscience Letters. 314: 45-8. PMID 11698143 DOI: 10.1016/S0304-3940(01)02277-7  0.432
2001 Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neuroscience. 4: 887-93. PMID 11528419 DOI: 10.1038/Nn0901-887  0.788
2001 Ingelson M, Fabre SF, Lilius L, Andersen C, Viitanen M, Almkvist O, Wahlund LO, Lannfelt L. Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E epsilon4. Neuroreport. 12: 905-9. PMID 11303757 DOI: 10.1097/00001756-200104170-00008  0.338
2001 Fabre SF, Forsell C, Viitanen M, Sjögren M, Wallin A, Blennow K, Blomberg M, Andersen C, Wahlund LO, Lannfelt L. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Experimental Neurology. 168: 413-8. PMID 11259129 DOI: 10.1006/Exnr.2000.7613  0.498
2001 Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK. Molecular consequences of presenilin-1 mutation Nature. 411: 655-655. DOI: 10.1038/35079684  0.427
2000 Andersen C, Froelich Fabre S, Ostberg P, Lannfelt L, Wahlund L. Tau protein in cerebrospinal fluid from semantic dementia patients. Neuroscience Letters. 294: 155-8. PMID 11072138 DOI: 10.1016/S0304-3940(00)01566-4  0.417
2000 Lannfelt L, Nordstedt C. Genetics of Alzheimer's disease--routes to the pathophysiology. Journal of Neural Transmission. Supplementum. 59: 155-61. PMID 10961427 DOI: 10.1007/978-3-7091-6781-6_17  0.44
2000 Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Näslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Molecular Medicine (Cambridge, Mass.). 6: 291-302. PMID 10949910 DOI: 10.1007/Bf03401938  0.445
2000 Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK. Presenilin-1 mutations in Alzheimer's disease. Nature. 405: 531-2. PMID 10850703 DOI: 10.1038/35014735  0.555
2000 Mattila KM, Axelman K, Rinne JO, Blomberg M, Lehtimäki T, Laippala P, Röyttä M, Viitanen M, Wahlund L, Winblad B, Lannfelt L. Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. Neuroscience Letters. 282: 45-8. PMID 10713392 DOI: 10.1016/S0304-3940(00)00849-1  0.415
2000 Andersen C, Jensen M, Lannfelt L, Lindau M, Wahlund LO. Amyloid Abeta40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia. Neuroreport. 11: 287-90. PMID 10674472  0.424
2000 Johnston JA, Jensen M, Lannfelt L, Walker B, Williams C. Inhibition of Prolylendopeptidase does not affect γ-secretase processing of amyloid precursor protein Biochemical Society Transactions. 28. DOI: 10.1042/Bst028A033C  0.396
2000 Stenh C, Lannfelt L, Nilsberth C. Effects of intra-Aβ mutations on Aβ secretion from transiently transfected cells Neurobiology of Aging. 21: 247. DOI: 10.1016/S0197-4580(00)83451-X  0.755
2000 Bergman A, Lannfelt L, Naslund J. Cell-free system studies of proteolytic activities generating the Alzheimer's disease Aβ peptide C termini Neurobiology of Aging. 21: 46. DOI: 10.1016/S0197-4580(00)82883-3  0.343
2000 Basun H, Eckman CB, Nilsberth C, Lannfelt L, Younkin SG. Plasma Aβ40 and Aβ42 in Alzheimer's patients during treatment with tacrine Neurobiology of Aging. 21: 91. DOI: 10.1016/S0197-4580(00)82632-9  0.735
2000 Lilius L, Axelman K, Lannfelt L. Effect of apolipoproteinβ4 and tau gene polymorphisms on age of onset in Swedish Alzheimer's disease sib-pairs Neurobiology of Aging. 21: 63. DOI: 10.1016/S0197-4580(00)82505-1  0.327
2000 Bjors J, Nilsberth C, Naslund J, Lannfelt L. Accumulation of intracellular amyloid ß peptide in Alzheimer's disease Neurobiology of Aging. 21: 200. DOI: 10.1016/S0197-4580(00)82240-X  0.743
2000 Ingelson M, Fabre SF, Volkmann I, Basun H, Naslund JD, Lannfelt L, Bogdanovic N. Tau with three and four microtubule-binding repeats in human brain of Alzheimer's disease and frontotemporal dementia Neurobiology of Aging. 21: 197. DOI: 10.1016/S0197-4580(00)82230-7  0.316
2000 Blomberg ME, Ingelson M, Jensen M, Engvall B, Julin P, Basun H, Lannfelt L, Wahlund L. Regional brain volumes, cerebrospinal fluid tau and amyloid β peptide in Alzheimer's disease and mild cognitive impairment Neurobiology of Aging. 21: 164. DOI: 10.1016/S0197-4580(00)82076-X  0.319
1999 Johnston JA, Jensen M, Lannfelt L, Walker B, Williams CH. Inhibition of prolylendopeptidase does not affect gamma-secretase processing of amyloid precursor protein in a human neuroblastoma cell line. Neuroscience Letters. 277: 33-6. PMID 10643891 DOI: 10.1016/S0304-3940(99)00834-4  0.5
1999 Lilius L, Froelich Fabre S, Basun H, Forsell C, Axelman K, Mattila K, Andreadis A, Viitanen M, Winblad B, Fratiglioni L, Lannfelt L. Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's disease. Neuroscience Letters. 277: 29-32. PMID 10643890 DOI: 10.1016/S0304-3940(99)00833-2  0.455
1999 Wahlund LO, Basun H, Almkvist O, Julin P, Axelman K, Shigeta M, Jelic V, Nordberg A, Lannfelt L. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dementia and Geriatric Cognitive Disorders. 10: 526-33. PMID 10559570 DOI: 10.1159/000017200  0.466
1999 Mustafa A, Lannfelt L, Lilius L, Islam A, Winblad B, Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dementia and Geriatric Cognitive Disorders. 10: 446-51. PMID 10559558 DOI: 10.1159/000017188  0.378
1999 Ingelson M, Blomberg M, Benedikz E, Wahlund LO, Karlsson E, Vanmechelen E, Lannfelt L. Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dementia and Geriatric Cognitive Disorders. 10: 442-5. PMID 10559557 DOI: 10.1159/000017187  0.33
1999 Savioz A, Leuba G, Forsell C, Lilius L, Rossier C, Saini K, Bouras C, Lannfelt L. No detected mutations in the genes for the amyloid precursor protein and presenilins 1 and 2 in a swiss early-onset Alzheimer's disease family with a dominant mode of inheritance. Dementia and Geriatric Cognitive Disorders. 10: 431-6. PMID 10559555 DOI: 10.1159/000017185  0.456
1999 Nilsberth C, Luthman J, Lannfelt L, Schultzberg M. Expression of presenilin 1 mRNA in rat peripheral organs and brain. The Histochemical Journal. 31: 515-23. PMID 10507458 DOI: 10.1023/A:1003887922777  0.723
1999 Kowalska A, Forsell C, Florczak J, Pruchnik-WoliÅ„ska D, Modestowicz R, Paprzycki W, Wender M, Lannfelt L. A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization. Folia Neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 37: 57-61. PMID 10337065  0.362
1999 Sheu KF, Brown AM, Kristal BS, Kalaria RN, Lilius L, Lannfelt L, Blass JP. A DLST genotype associated with reduced risk for Alzheimer's disease. Neurology. 52: 1505-7. PMID 10227647 DOI: 10.1212/Wnl.52.7.1505  0.416
1999 Jensen M, Schröder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Annals of Neurology. 45: 504-11. PMID 10211475 DOI: 10.1002/1531-8249(199904)45:4<504::Aid-Ana12>3.0.Co;2-9  0.429
1999 Vestling M, Cedazo-Mínguez A, Adem A, Wiehager B, Racchi M, Lannfelt L, Cowburn RF. Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases. Biochimica Et Biophysica Acta. 1453: 341-50. PMID 10101252 DOI: 10.1016/S0925-4439(99)00003-4  0.524
1999 Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F, Milman P, Holmes E, Liang Y, Kawarai T, Jo E, Supala A, Rogaeva E, Xu DM, Janus C, ... ... Lannfelt L, et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nature Medicine. 5: 164-9. PMID 9930863 DOI: 10.1038/5526  0.429
1999 Sheu KF, Brown AM, Haroutunian V, Kristal BS, Thaler H, Lesser M, Kalaria RN, Relkin NR, Mohs RC, Lilius L, Lannfelt L, Blass JP. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population. Annals of Neurology. 45: 48-53. PMID 9894876 DOI: 10.1002/1531-8249(199901)45:1<48::Aid-Art9>3.0.Co;2-V  0.44
1998 Mattila KM, Forsell C, Pirttilä T, Rinne JO, Lehtimäki T, Röyttä M, Lilius L, Eerola A, St George-Hyslop PH, Frey H, Lannfelt L. The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. Annals of Neurology. 44: 965-7. PMID 9851443 DOI: 10.1002/Ana.410440617  0.551
1998 Almkvist O, Basun H, Bäckman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Winblad B. Mild cognitive impairment--an early stage of Alzheimer's disease? Journal of Neural Transmission. Supplementum. 54: 21-9. PMID 9850912 DOI: 10.1007/978-3-7091-7508-8_3  0.338
1998 Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of APOE polymorphisms in late-onset dementias. Cellular and Molecular Life Sciences : Cmls. 54: 928-34. PMID 9791536 DOI: 10.1007/S000180050223  0.493
1998 Gibson GE, Zhang H, Sheu KF, Bogdanovich N, Lindsay JG, Lannfelt L, Vestling M, Cowburn RF. Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Annals of Neurology. 44: 676-81. PMID 9778267 DOI: 10.1002/Ana.410440414  0.547
1998 Yamada H, Dahl ML, Viitanen M, Winblad B, Sjöqvist F, Lannfelt L. No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Alzheimer Disease and Associated Disorders. 12: 204-7. PMID 9772024 DOI: 10.1097/00002093-199809000-00013  0.385
1998 Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, Hall C. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nature Medicine. 4: 1182-4. PMID 9771753 DOI: 10.1038/2677  0.326
1998 Reznik-Wolf H, Machado J, Haroutunian V, DeMarco L, Walter GF, Goldman B, Davidson M, Johnston JA, Lannfelt L, Dani SU, Friedman E. Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer's disease brains. Journal of Neurogenetics. 12: 55-65. PMID 9666901 DOI: 10.3109/01677069809108555  0.517
1998 Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, ... ... Lannfelt L, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393: 702-5. PMID 9641683 DOI: 10.1038/31508  0.441
1998 Kowalska A, Wender M, Lannfelt L. Lack of association between an intronic polymorphism in the presenilin-1 gene and sporadic late-onset Alzheimer disease in Polish patients. Dementia and Geriatric Cognitive Disorders. 9: 137-9. PMID 9622000 DOI: 10.1159/000017037  0.374
1998 Axelman K, Basun H, Lannfelt L. Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. Archives of Neurology. 55: 698-702. PMID 9605727  0.408
1998 Jelic V, Blomberg M, Dierks T, Basun H, Shigeta M, Julin P, Jensen M, Lannfelt L, Winblad B, Wahlund LO. EEG slowing and cerebrospinal fluid tau levels in patients with cognitive decline. Neuroreport. 9: 157-60. PMID 9592068 DOI: 10.1097/00001756-199801050-00032  0.304
1998 Lannfelt L. Biochemical diagnostic markers to detect early Alzheimer's disease. Neurobiology of Aging. 19: 165-7. PMID 9558156 DOI: 10.1016/S0197-4580(98)00012-8  0.538
1998 Davies P, Resnick J, Resnick B, Gilman S, Growdon JH, Khachaturian ZS, Radebaugh TS, Roses AD, Selkoe DJ, Trojanowski JQ, Blass JP, Gibson GE, Sheu KFR, Blennow K, Delacourte A, ... ... Lannfelt L, et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' Neurobiology of Aging. 19: 109-116. PMID 9558143 DOI: 10.1016/S0197-4580(98)00022-0  0.571
1998 Julin P, Almkvist O, Basun H, Lannfelt L, Svensson L, Winblad B, Wahlund LO. Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer amyloid protein mutation. Alzheimer Disease and Associated Disorders. 12: 49-53. PMID 9539411 DOI: 10.1097/00002093-199803000-00008  0.369
1997 Johnston JA, Lannfelt L, Wiehager B, O'Neill C, Cowburn RF. Amyloid precursor protein heat shock response in lymphoblastoid cell lines bearing presenilin-1 mutations. Biochimica Et Biophysica Acta. 1362: 183-92. PMID 9540849 DOI: 10.1016/S0925-4439(97)00074-4  0.461
1997 Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L, Gandy S, Cowburn RF. Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. Neurobiology of Aging. 18: 573-80. PMID 9461055 DOI: 10.1016/S0197-4580(97)00149-8  0.484
1997 Forsell C, Froelich S, Axelman K, Vestling M, Cowburn RF, Lilius L, Johnston JA, Engvall B, Johansson K, Dahlkild A, Ingelson M, St George-Hyslop PH, Lannfelt L. A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease. Neuroscience Letters. 234: 3-6. PMID 9347932 DOI: 10.1016/S0304-3940(97)00603-4  0.484
1997 Svensson AL, Warpman U, Hellström-Lindahl E, Bogdanovic N, Lannfelt L, Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neuroscience Letters. 232: 37-40. PMID 9292886 DOI: 10.1016/S0304-3940(97)00573-9  0.391
1997 Shanahan C, Gibson GE, Cowburn RF, Johnston JA, Wiehager B, Lannfelt L, O'Neill C. G protein subunit levels in fibroblasts from familial Alzheimer's disease patients: lower levels of high molecular weight Gs alpha isoform in patients with decreased beta-adrenergic receptor stimulated cAMP formation. Neuroscience Letters. 232: 33-6. PMID 9292885 DOI: 10.1016/S0304-3940(97)00572-7  0.339
1997 Froelich S, Basun H, Forsell C, Lilius L, Axelman K, Andreadis A, Lannfelt L. Mapping of a disease locus for familial rapidly progressive frontotemporal dementia to chromosome 17q12-21. American Journal of Medical Genetics. 74: 380-5. PMID 9259373 DOI: 10.1002/(Sici)1096-8628(19970725)74:4<380::Aid-Ajmg8>3.0.Co;2-T  0.326
1997 Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, März W, Wahlund LO, Cowburn RF. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neuroscience Letters. 229: 85-8. PMID 9223597 DOI: 10.1016/S0304-3940(97)00429-1  0.444
1997 Vestling M, Adem A, Racchi M, Gibson GE, Lannfelt L, Cowburn RF. Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. Neuroreport. 8: 2031-5. PMID 9223097  0.44
1997 Jelic V, Julin P, Shigeta M, Nordberg A, Lannfelt L, Winblad B, Wahlund LO. Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. Journal of Neurology, Neurosurgery, and Psychiatry. 63: 59-65. PMID 9221969 DOI: 10.1136/Jnnp.63.1.59  0.312
1997 Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Archives of Neurology. 54: 641-4. PMID 9152122 DOI: 10.1001/Archneur.1997.00550170111022  0.429
1997 Corder EH, Jelic V, Basun H, Lannfelt L, Valind S, Winblad B, Nordberg A. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Archives of Neurology. 54: 273-7. PMID 9074396 DOI: 10.1001/Archneur.1997.00550150035013  0.319
1996 Algotsson A, Nordberg A, Lannfelt L, Almkvist O, Winblad B. Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. Archives of Gerontology and Geriatrics. 22: 223-32. PMID 15374172 DOI: 10.1016/0167-4943(96)00695-4  0.368
1996 Johnston JA, Norgren S, Ravid R, Wasco W, Winblad B, Lannfelt L, Cowburn RF. Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Brain Research. Molecular Brain Research. 43: 85-95. PMID 9037522 DOI: 10.1016/S0169-328X(96)00161-1  0.498
1996 Johnston JA, Norgren S, Annerén G, Cowburn RF, Lannfelt L. A new quantitative solution hybridisation-RNase protection assay for APP and APLP2 mRNA. Brain Research. Molecular Brain Research. 43: 77-84. PMID 9037521 DOI: 10.1016/S0169-328X(96)00160-X  0.377
1996 Lannfelt L. Genetics of Alzheimer's disease. Acta Neurologica Scandinavica. Supplementum. 168: 25-7. PMID 8997415 DOI: 10.1111/J.1600-0404.1996.Tb00368.X  0.568
1996 Ingelson M, Vanmechelen E, Lannfelt L. Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. Neuroscience Letters. 220: 9-12. PMID 8977136 DOI: 10.1016/S0304-3940(96)13218-3  0.558
1996 Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neuroscience Letters. 214: 163-6. PMID 8878109 DOI: 10.1016/0304-3940(96)12905-0  0.492
1996 Kalaria RN, Cohen DL, Greenberg BD, Savage MJ, Bogdanovic NE, Winblad B, Lannfelt L, Adem A. Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. Neuroreport. 7: 1377-81. PMID 8856679 DOI: 10.1097/00001756-199605310-00009  0.416
1996 Johnston JA, Froelich S, Lannfelt L, Cowburn RF. Quantification of presenilin-1 mRNA in Alzheimer's disease brains. Febs Letters. 394: 279-84. PMID 8830658 DOI: 10.1016/0014-5793(96)00969-6  0.42
1996 Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, Levesque G, Rogaev EI, Lin C, Liang Y, Ikeda M, Mar L, Brice A, Agid Y, Percy ME, ... ... Lannfelt L, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Human Molecular Genetics. 5: 985-8. PMID 8817335 DOI: 10.1093/Hmg/5.7.985  0.504
1996 Liu L, Forsell C, Lilius L, Axelman K, Corder EH, Lannfelt L. Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late-onset Swedish Alzheimer families. American Journal of Medical Genetics. 67: 306-11. PMID 8725748 DOI: 10.1002/(Sici)1096-8628(19960531)67:3<306::Aid-Ajmg7>3.0.Co;2-K  0.447
1996 Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, ... ... Lannfelt L, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine. 2: 864-70. PMID 8705854 DOI: 10.1038/Nm0896-864  0.479
1996 Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. The American Journal of Pathology. 148: 1257-66. PMID 8644866  0.353
1996 Bogdanovic N, Lannfelt L, Winblad B. 776 Neuropathological study of Alzheimer's disease caused by “Swedish” duble mutation at APP gene on chromosome 21 Neurobiology of Aging. 17: S193. DOI: 10.1016/S0197-4580(96)80778-0  0.409
1996 Ahnkvist O, Basun H, Jensen M, Wahlund L, Wagner S, Lannfelt L. 676 Levels of α-APP in CSF are correlated with cognitive function in members of the Swedish amyloid mutation family Neurobiology of Aging. 17: S168. DOI: 10.1016/S0197-4580(96)80678-6  0.307
1996 Amberla K, Ahnkvist O, Basun H, Jensen M, Viitanen M, Wahlund L, Lannfelt L. 669 Tau levels in CSF are related to cognitive functions in familial Alzheimer's disease Neurobiology of Aging. 17: S166-S167. DOI: 10.1016/S0197-4580(96)80671-3  0.31
1996 Lannfelt L, Lilius L, Forsell C, Axelman K, Engvall B, Froelich S, Basun B, Andreadis A. 599 Candidate genes for Alzheimer's disease Neurobiology of Aging. 17: S149. DOI: 10.1016/S0197-4580(96)80601-4  0.326
1996 Wang R, Chait B, Peskinde E, Schellenberge G, Farlow M, Lannfelt L, Wagners S. 408 Mass spectrometric analysis of amyloid β-peptides in cerebrospinal fluid specimens from affected and unaffected carriers of familial alzheimer's disease associated genetic mutations Neurobiology of Aging. 17: S102. DOI: 10.1016/S0197-4580(96)80410-6  0.387
1996 Ingelson M, Lannfelt L. 405 Tau in fibroblasts with and without the Swedish APP 670/671 mutation Neurobiology of Aging. 17: S101. DOI: 10.1016/S0197-4580(96)80407-6  0.377
1996 Leuba G, Lannfelt L, Forsell C, Lilius L, Schwed P, Baeriswyl F, Saini K. 241 Early onset familial Alzheimer's disease with an apoE4 genotype but without APP mutation : Description of the pedigree and clinicopathological data Neurobiology of Aging. 17: S61. DOI: 10.1016/S0197-4580(96)80243-0  0.424
1996 Froelich S, Engvall B, Forsell C, Hillert J, Lannfelt L. 236 A search for susceptibility genes in late-onset Alzheimer's disease Neurobiology of Aging. 17: S59. DOI: 10.1016/S0197-4580(96)80238-7  0.328
1996 Lindh M, Blomberg M, Jensen M, Wahlund L, März W, Scharnagl H, Lannfelt L, Cowburn R. 235 Apolipoprotein E levels in plasma and CSF from members of the Swedish Alzheimer's disease APP 670/671 mutation family and sporadic Alzheimer's disease cases Neurobiology of Aging. 17: S59. DOI: 10.1016/S0197-4580(96)80237-5  0.433
1996 Younkin S, Scheuner D, Song X, Eckman C, Citron M, Suzuki N, Bird T, Hardy J, Hutton M, Lannfelt L, Levy-Lahad E, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, et al. 149 The Presenilin 1 and 2 mutations linked to familial Alzheimer's Disease increase the extracellular concentration of amyloid 0 protein (Aβ) ending at Aβ42(43) Neurobiology of Aging. 17. DOI: 10.1016/S0197-4580(96)80151-5  0.512
1996 Vestling M, Adem A, Racchi M, Govoni S, Lannfelt L, Cowbum R. 80 β-adrenoreceptor-stimulated adenylyl cyclase activity in skin fibroblasts from sporadic, presenilin-1 mutation carrying and APP 670/671 mutation carrying Alzheimer's disease cases Neurobiology of Aging. 17: S20. DOI: 10.1016/S0197-4580(96)80082-0  0.362
1996 Reznik-Wolf H, Machado J, Haroutunlan V, DeMarco L, Walter GF, Chapman Y, Goldman B, Dasvidson M, Johnston J, Lannfelt L, Dani SU, Friedman E. 55 Somatic mutational analyses of the APP and Presenillin 1 genes in Alzheimer's disease patients brains using Denaturing Gradient Gel Electrophoresis (DGGE) Neurobiology of Aging. 17: S14. DOI: 10.1016/S0197-4580(96)80057-1  0.401
1996 Forsell C, Froelich S, Axelman K, St George-Hyslop P, Lannfelt L. 50 Mutations in the presenilin I and II genes are rare in early-onset Alzheimer's disease in Sweden Neurobiology of Aging. 17: S13. DOI: 10.1016/S0197-4580(96)80052-2  0.375
1996 Axelman K, Lannfelt L. 49 Variable age of onset in an alzheimer family with a His163Tyr mutation in the presenilin 1 gene Neurobiology of Aging. 17: S13. DOI: 10.1016/S0197-4580(96)80051-0  0.323
1996 Younkin SG, Song XH, Scheuner D, Eckman C, Prada C, Jensen J, Lannfelt L, Hardy J, Tanzi R, Schellenberg G, Selkoe D, Suzuki N. The effect of amyloid precursor protein and presenilin mutations on amyloid beta protein Biological Psychiatry. 39: 562. DOI: 10.1016/0006-3223(96)84161-8  0.369
1995 Lannfelt L, Basun H, Vigo-Pelfrey C, Wahlund LO, Winblad B, Lieberburg I, Schenk D. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neuroscience Letters. 199: 203-6. PMID 8577398 DOI: 10.1016/0304-3940(95)12059-D  0.6
1995 Lannfelt L, Pedersen NL, Lilius L, Axelman K, Johansson K, Viitanen M, Gatz M. Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease. Alzheimer Disease and Associated Disorders. 9: 166-9. PMID 8534415 DOI: 10.1097/00002093-199500930-00008  0.431
1995 Lannfelt L, Axelman K, Lilius L, Basun H. Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. American Journal of Human Genetics. 56: 332-5. PMID 7825596  0.406
1995 Lannfelt L, Lilius L, Viitanen M, Houlden H, Rossor M, Hardy J, Winblad B, Basun H. Microsatellite D21S210 (GT-12) allele frequencies in sporadic Alzheimer's disease. Acta Neurologica Scandinavica. 91: 145-8. PMID 7785426 DOI: 10.1111/J.1600-0404.1995.Tb00422.X  0.497
1995 Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neuroscience Letters. 186: 189-91. PMID 7777193 DOI: 10.1016/0304-3940(95)11297-A  0.507
1995 Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. Neuroscience Letters. 183: 32-4. PMID 7746480 DOI: 10.1016/0304-3940(94)11107-T  0.451
1995 Forsell C, Lannfelt L. Amyloid precursor protein mutation at codon 713 (Ala-->Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent). Neuroscience Letters. 184: 90-3. PMID 7724053 DOI: 10.1016/0304-3940(94)11176-J  0.528
1995 Jönsson E, Forsell C, Lannfelt L, Sedvall G. Schizophrenia and APP gene mutations. Biological Psychiatry. 37: 135-6. PMID 7718679 DOI: 10.1016/0006-3223(94)00211-K  0.331
1995 Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, ... ... Lannfelt L, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Nature. 376: 775-778. PMID 7651536 DOI: 10.1038/376775A0  0.477
1995 Näslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlström AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron. 15: 219-28. PMID 7619525 DOI: 10.1016/0896-6273(95)90079-9  0.381
1995 Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nature Medicine. 1: 829-32. PMID 7585189 DOI: 10.1038/Nm0895-829  0.586
1995 Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nature Medicine. 1: 1291-6. PMID 7489411 DOI: 10.1038/Nm1295-1291  0.378
1995 Lannfelt L, Pedersen NL, Lilius L, Axelman K, Johansson K, Viitanen M, Gatz M. Apolipoprotein ∊4 Allele in Swedish Twins and Siblings with Alzheimer Disease Alzheimer Disease & Associated Disorders. 9: 166-169. DOI: 10.1097/00002093-199509030-00008  0.354
1995 Lannfelt L, Pedersen NL, Lilius L, Axelman K, Johansson K, Viitanen M, Gatz M. Apolipoprotein ε4 Allele in Swedish Twins and Siblings with Alzheimer Disease Alzheimer Disease & Associated Disorders. 9: 166-169. DOI: 10.1097/00002093-199500930-00008  0.355
1994 Lannfelt L, Johnston J, Bogdanovich N, Cowburn R. Amyloid precursor protein gene mutation at codon 670/671 in familial Alzheimer's disease in Sweden. Biochemical Society Transactions. 22: 176-9. PMID 8206219 DOI: 10.1042/Bst0220176  0.55
1994 Norstedt C, Lannfelt L, Winblad B. Alzheimer's disease: a molecular perspective. Journal of Internal Medicine. 235: 195-8. PMID 8120513 DOI: 10.1111/J.1365-2796.1994.Tb01059.X  0.328
1994 Lilius L, Lannfelt L. No amyloid precursor protein 708 mutation in 50 Swedish Alzheimer's disease patients. Human Genetics. 93: 227-8. PMID 8112758 DOI: 10.1007/Bf00210624  0.563
1994 Haltia M, Viitanen M, Sulkava R, Ala-Hurula V, Poyhonen M, Goldfarb L, Brown P, Levy E, Houlden H, Crook R, Goate A, Clark R, Korenblat K, Pandit S, Keller HD, ... ... Lannfelt L, et al. Chromosome 14-encoded Alzheimer's disease: Genetic and clinicopathological description Annals of Neurology. 36: 362-367. PMID 8080244 DOI: 10.1002/Ana.410360307  0.483
1994 Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proceedings of the National Academy of Sciences of the United States of America. 91: 8378-82. PMID 8078890 DOI: 10.1073/Pnas.91.18.8378  0.331
1994 Lannfelt L, Lilius L, Nastase M, Viitanen M, Fratiglioni L, Eggertsen G, Berglund L, Angelin B, Linder J, Winblad B. Lack of association between apolipoprotein E allele epsilon 4 and sporadic Alzheimer's disease. Neuroscience Letters. 169: 175-8. PMID 8047277 DOI: 10.1016/0304-3940(94)90384-0  0.485
1994 Lannfelt L, Bogdanovic N, Appelgren H, Axelman K, Lilius L, Hansson G, Schenk D, Hardy J, Winblad B. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neuroscience Letters. 168: 254-6. PMID 8028788 DOI: 10.1016/0304-3940(94)90463-4  0.575
1994 Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proceedings of the National Academy of Sciences of the United States of America. 91: 11993-7. PMID 7991571 DOI: 10.1073/Pnas.91.25.11993  0.316
1994 Axelman K, Basun H, Winblad B, Lannfelt L. A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation. Archives of Neurology. 51: 1193-7. PMID 7986173 DOI: 10.1001/Archneur.1994.00540240037013  0.428
1994 Johnston JA, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B, Vigo-Pelfrey C, Schenk D, Lannfelt L, O'Neill C. Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. Febs Letters. 354: 274-8. PMID 7957938 DOI: 10.1016/0014-5793(94)01137-0  0.535
1994 Johnston J, O'Neill C, Lannfelt L, Winblad B, Cowburn RF. The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis. Neurochemistry International. 25: 73-80. PMID 7950974 DOI: 10.1016/0197-0186(94)90056-6  0.601
1994 Johnston J, Cowburn R, Wiehager B, Norgren S, Lannfelt L, Vigo-Pelfrey C, Schenk D, Citron M, Selkoe D, O'Neill C. Amyloid precursor protein expression and β-amyloid release in fibroblast cell lines obtained from family members with the Swedish APP670/671 mutation Neurobiology of Aging. 15: S71. DOI: 10.1016/0197-4580(94)92743-X  0.36
1993 Lannfelt L, Viitanen M, Johansson K, Axelman K, Lilius L, Almqvist E, Winblad B. Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden. Neuroscience Letters. 153: 85-7. PMID 8510829 DOI: 10.1016/0304-3940(93)90083-W  0.52
1993 Johnston J, Lilius L, Axelman K, Cowburn R, Johansson K, Viitanen M, Winblad B, Lannfelt L. Sequencing of exons 16 and 17 of the beta-amyloid precursor protein gene fails to identify new mutations in Swedish Alzheimer's disease patients. Human Molecular Genetics. 2: 1045-6. PMID 8364541 DOI: 10.1093/Hmg/2.7.1045  0.519
1993 Lannfelt L, Lilius L, Appelgren H, Axelman K, Forsell C, Liu L, Johansson K, Graff C. No linkage to chromosome 14 in Swedish Alzheimer's disease families. Nature Genetics. 4: 218-9. PMID 8358427 DOI: 10.1038/Ng0793-218  0.39
1993 Lannfelt L, Folkesson R, Mohammed AH, Winblad B, Hellgren D, Duff K, Hardy J. Alzheimer's disease: molecular genetics and transgenic animal models. Behavioural Brain Research. 57: 207-13. PMID 8117426 DOI: 10.1016/0166-4328(93)90137-F  0.538
1992 Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nature Genetics. 1: 345-7. PMID 1302033 DOI: 10.1038/Ng0892-345  0.546
1989 Lannfelt L, Wetterberg L, Gellerfors P, Lilius L, Floderus Y, Thunell S. Mutations in acute intermittent porphyria detected by ELISA measurement of porphobilinogen deaminase. Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fã¼R Klinische Chemie Und Klinische Biochemie. 27: 857-62. PMID 2607315 DOI: 10.1515/Cclm.1989.27.11.857  0.329
Show low-probability matches.